Skip to Main Content

Paper Details

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
Lancet Oncol
47
2022
*03 allele, A*03 allele, HLA, HLA amino, HLA loci, HLA molecules, HLA-, HLA-A, HLA-A*, HLA-A*03, HLA-A*03 allele, HLA-A*03 heterozygotes, HLA-A*03 homozygotes, Patients, Solid Tumour, advanced cancer, advanced cancers, advanced tumours, amino-acid, anti-CTLA, anti-PD-1, anti-PD-L1, axitinib, bladder cancer, cancer, everolimus, patient, patients, renal cell carcinoma, sunitinib, tumour
Author NameAffiliation
Vivek NaranbhaiMassachusetts General Hospital, USA Dana-Farber Cancer Institute
Michael DeanNational Cancer Institute
Yuko YukiFrederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute
Toni K ChoueiriDana-Farber Cancer Institute
Mary CarringtonFrederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, USA Ragon Institute of MGH
Mary CarringtonFrederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, USA Ragon Institute of MGH
  • 1 - 6

Datasets

Release 1.2